Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
E Giuliani Meredith, Edith Filion, Sergio Faria, Vijayananda Kundapur, Toni Vu Thi Trinh Thuc, Benjamin H Lok, Srinivas Raman, Houda Bahig, Joanna M Laba, Pencilla Lang, Alexander V Louie, Andrew Hope, George B Rodrigues, Andrea Bezjak, Marie-Pierre Campeau, Marie Duclos, Scott Bratman, Anand Swaminath, Rohan Salunkhe, Andrew Warner, David A Palma
INTRODUCTION: The use of stereotactic body radiotherapy (SBRT) for tumors in close proximity to the central mediastinal structures has been associated with a high risk of toxicity. This study (BLINDED FOR REVIEW) aimed to determine the maximally tolerated dose (MTD) of SBRT for ultra-central (UC) non-small cell lung carcinoma (NSCLC), using a time-to-event continual reassessment methodology (TITE-CRM). METHODS: Patients with T1-3N0M0 (≤ 6 cm) NSCLC were eligible...
April 11, 2024: International Journal of Radiation Oncology, Biology, Physics
#2
JOURNAL ARTICLE
Melissa O'Neil, Joanna M Laba, Timothy K Nguyen, Michael Lock, Christopher D Goodman, Elizabeth Huynh, Jonatan Snir, Vikki Munro, Jenna Alce, Lidia Schrijver, Sylvia Lemay, Tara MacDonald, Andrew Warner, David A Palma
PURPOSE: Using diagnostic computed tomography (dCT) scans instead of CT simulation (CTsim) scans can increase departmental efficiency and reduce patient burden. The goal of the DART trial was to assess the efficacy and acceptability of dCT-based planning workflows with a focus on patient experiences, plan deliverability and adequacy of target coverage, and workflows. METHODS AND MATERIALS: Patients undergoing same-day CTsim and treatment for palliative radiation therapy to thoracic, abdominopelvic, or proximal limb targets with a recent dCT (within 28 days) in a reproducible position were eligible...
April 12, 2024: International Journal of Radiation Oncology, Biology, Physics
#3
JOURNAL ARTICLE
Mei Sheng Duh, Melissa H Roberts, Kieran J Rothnie, Wendy Y Cheng, Philippe Thompson-Leduc, Shiyuan Zhang, Alexandrosz Czira, David Slade, Alexandra Greatsinger, Adina Zhang, Douglas Mapel
INTRODUCTION: Despite adherence to inhaled corticosteroid/long-acting β2 -agonist (ICS/LABA) therapy, many patients with asthma experience moderate exacerbations. Data on the impact of moderate exacerbations on the healthcare system are limited. This study assessed the frequency and economic burden of moderate exacerbations in patients receiving ICS/LABA. METHODS: Retrospective, longitudinal study analyzed data from Optum's de-identified Clinformatics® Data Mart Database recorded between October 1, 2015, and December 31, 2019...
April 7, 2024: Respiratory Medicine
#4
JOURNAL ARTICLE
Rachael Mountain, Kevin I Duan, Kate Johnson
Rationale: Reducing the risk of exacerbation is a fundamental goal in managing stable COPD. Guidelines recommend triple therapy (inhaled corticosteroids, long-acting muscarinic antagonists, and long-acting beta-agonists [ICS/LAMA/LABA]) only as a step-up from dual therapy (LAMA/LABA) for patients at continued high risk of exacerbation, due to the trade-off of an increased risk of pneumonia associated with ICS-containing therapies. However, there is little evidence on the optimum timing of initiating triple therapy...
April 5, 2024: Annals of the American Thoracic Society
#5
JOURNAL ARTICLE
Manuela Latorre, Angela Rizzi, Pierluigi Paggiaro, Ilaria Baiardini, Diego Bagnasco, Stefano DelGiacco, Carlo Lombardi, Vincenzo Patella, Eleonora Nucera, Roberta Parente, Giovanni Paoletti, Laura Pini, Erminia Ridolo, Gianenrico Senna, Francesco Blasi, Giorgio Walter Canonica, Arianna Aruanno, Carmen Ballacchino, Marco Bonavia, Cecilia Calabrese, Marco Caminati, Monica Carbonara, Cristina Cardini, Cristiano Caruso, Luciano Cattani, Maria Angiola Crivellaro, Alessandra Diana, Eugenia Durante, Elisabetta Favero, Maria Pia Foschino Barbaro, Sandra Frateiacci, Gabriella Guarnieri, Alessia Lofaro, Francesca Losa, Nadia Magarò, Francesco Menzella, Luisa Ricciardi, Giulia Scioscia, Elisa Testino, Francesca Torracca
OBJECTIVE: Patients' perceptions of asthma symptoms, and attitudes regarding diagnosis and management, can affect their ability to reach good asthma control. The aim of the study was to explore patients' perceptions of asthma management, with focus on treatment with oral corticosteroids (OCS). METHODS: A DOXAPHARMA survey was conducted. A questionnaire with 46 multiple choice questions was completed by 50 patients with severe uncontrolled asthma, and 258 with mild-moderate controlled or partly controlled asthma...
April 5, 2024: Journal of Asthma
#6
JOURNAL ARTICLE
Frederik Trinkmann
BACKGROUND: Diagnostic and therapeutic options for asthma have improved with asthma control and remission being of central importance. The RELEVANT study aimed for a nationwide snapshot of current asthma diagnosis and treatment in general practice and specialty care for identification of further aspects for optimization. METHOD: RELEVANT is a nationwide cross-sectional study using a structured questionnaire. This comprised 14 questions on asthma-related topics covering diagnostics and therapy...
April 2024: MMW Fortschritte der Medizin
#7
Bianca Oprescu, Oana Raduna, Stefan Mihaicuta, Stefan Frent
Background and Objectives : Severe adult-onset eosinophilic asthma and COPD with eosinophilic inflammation are two entities with a similar clinical course and are sometimes difficult to differentiate in clinical practice, especially in patients with a history of smoking. Anti-IL-5 or -IL-5R biological therapy has been shown to be highly effective in severe eosinophilic asthma but has not demonstrated significant benefit in patients with COPD with the eosinophilic phenotype. Our aim was to illustrate this issue in the form of a case report...
February 25, 2024: Medicina
#8
JOURNAL ARTICLE
Sangmin Lee, Erin Hetherington, Richard Leigh, Kaylee Ramage, Amy Metcalfe
BACKGROUND: Asthma affects 5% to 13% of pregnant women, and many require daily pharmacotherapy to achieve asthma control; however, adherence to medication during pregnancy often decreases. OBJECTIVE: To understand the association between the use of or adherence to asthma medication with asthma exacerbation and maternal/neonatal outcomes. METHODS: Using linked population-based administrative databases from Alberta, Canada (2012-2018), pregnant women with asthma were categorized based on asthma medication use 1 year before pregnancy: short-acting β-agonists (SABA), inhaled corticosteroids (ICS), and ICS with long-acting β-agonists (ICS+LABA)...
March 7, 2024: Journal of Allergy and Clinical Immunology in Practice
#9
REVIEW
Lisa M Kalisch Ellett, Jack L Janetzki, Renly Lim, Tracey-Lea Laba, Nicole L Pratt
Pharmacovigilance is defined by the World Health Organization as "the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine/vaccine related problem". Pharmacovigilance studies are critical for detecting and assessing adverse events of medicines that may not have been observed in clinical trials. This activity is especially important in older people who are often excluded from clinical trials as they have multiple chronic conditions and use multiple medicines for longer durations than the clinical trials...
March 26, 2024: British Journal of Clinical Pharmacology
#10
JOURNAL ARTICLE
Hnin Ww Aung, Claire E Boddy, Eleanor Hampson, Mark Bell, Lauren A Parnell, Kumaran Balasundaram, Anna C Murphy, Shamsa Naveed, Peter Bradding
BACKGROUND: 65% of people with severe asthma and a FeNO ≥45 ppb are non-adherent to inhaled corticosteroids (ICS). Digital devices recording both time-of-use and inhaler technique identify non-adherence and ICS responsiveness but are not widely available. As the NEXThaler™ dose counter only activates at an inspiratory flow of 35 L/min, this may provide an alternative to identifying ICS responsiveness. OBJECTIVE: To assess ICS adherence and responsiveness in severe asthma using beclometasone/formoterol (200/6 mcg) NEXThaler™ (BFN) dose-counting...
March 20, 2024: Journal of Allergy and Clinical Immunology in Practice
#11
JOURNAL ARTICLE
Hyun Woo Lee, Jiyu Sun, Hyo-Jin Lee, Jung-Kyu Lee, Tae Yeon Park, Eun Young Heo, Chin Kook Rhee, Deog Kyeom Kim
BACKGROUND: Roflumilast is effective in reducing acute exacerbation in patients with chronic obstructive pulmonary disease (COPD) at high risk of severe exacerbation. Clinical traits related to the benefits of roflumilast need to be evaluated in patients with COPD. METHODS: A longitudinal observational study in patients newly diagnosed with COPD was conducted using claims data from the Health Insurance Review and Assessment Service in South Korea from 2012-2020 after a 2-year washout period...
February 29, 2024: Journal of Thoracic Disease
#12
JOURNAL ARTICLE
Rayan Alsuwaigh, Anthony Yii, Chee Hong Loh, Xiaomeng Xu, Priti Bahety, Aldo A Navarro Rojas, Dominique Milea, Augustine Tee
BACKGROUND: In 2019 and 2023, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) provided updated strategies for modifying the therapy of patients with chronic obstructive pulmonary disease (COPD) and high exacerbation risk. A key update since the 2019 guidelines recommends considering blood eosinophil count to guide decisions on inhaled corticosteroid (ICS) treatment. To evaluate the potential impact of these updated recommendations, this study aimed to assess how extensively future practice would diverge from contemporaneous prescribing practices at a single center in Singapore, assuming adherence to the 2019 and 2023 GOLD guidelines...
February 29, 2024: Journal of Thoracic Disease
#13
Antonio Maiorano, Chiara Lupia, Nicola Montenegro, Giuseppe Neri, Andrea Bruni, Eugenio Garofalo, Federico Longhini, Claudia Crimi, Angelantonio Maglio, Alessandro Vatrella, Girolamo Pelaia, Corrado Pelaia
Beclomethasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) single inhaler extrafine triple therapy is effective for the treatment of uncontrolled asthma. Nevertheless, there is a lack of data about the use of diaphragmatic ultrasonography to monitor adult asthmatics while they are receiving inhaled treatment. We took into consideration a 78-year-old woman complaining of asthma, treated with inhaled corticosteroid/long-acting β2 -adrenergic agonist (ICS/LABA), characterized by an asthma control questionnaire-5 (ACQ-5) score and a lung function test suggestive of uncontrolled asthma...
2024: Frontiers in Medicine
#14
REVIEW
Maria Gabriella Matera, Barbara Rinaldi, Rosa Annibale, Vito De Novellis, Mario Cazzola
INTRODUCTION: The pharmacotherapy of asthma is a dynamic process that changes as our knowledge of the underlying pathophysiology and treatment of this disease continues to evolve. This implies the need for continuous revision of the recommendations of asthma guidelines and strategies. AREAS COVERED: This review summarizes the latest key practical information on the pharmacological management of asthma in adults. We provide the background to the 2023 update of the GINA strategy report, focusing on changes and discussing areas of uncertainty...
March 20, 2024: Expert Opinion on Pharmacotherapy
#15
JOURNAL ARTICLE
Paola Maria Cutroneo, Elena Arzenton, Fabiana Furci, Fabio Scapini, Maria Bulzomì, Nicoletta Luxi, Marco Caminati, Gianenrico Senna, Ugo Moretti, Gianluca Trifirò
BACKGROUND: The management of uncontrolled severe asthma has greatly improved since the advent of novel biologic therapies. Up to August 2022, five biologics have been approved for the type 2 asthma phenotype: anti-IgE (omalizumab), anti-IL5 (mepolizumab, reslizumab, benralizumab), and anti-IL4 (dupilumab) monoclonal antibodies. These drugs are usually well tolerated, although long-term safety information is limited, and some adverse events have not yet been fully characterized. Spontaneous reporting systems represent the cornerstone for the detection of potential signals and evaluation of the real-world safety of all marketed drugs...
March 15, 2024: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
#16
JOURNAL ARTICLE
Fang Jing, Shangli Shi, Wenjuan Kang, Jian Guan, Baofu Lu, Bei Wu, Wenjuan Wang
Plant height plays an important role in crop yield, product quality, and cultivation management. However, the physiological mechanisms that regulate the establishment of plant height in alfalfa plants remain unclear. Herein, we measured plant height traits, leaf characteristics, photosynthetic physiology, cell wall composition, and endogenous hormone contents of tall- and short-stalked alfalfa materials at different reproductive periods. We analyzed the physiology responsible for differences in plant height...
February 28, 2024: Plants (Basel, Switzerland)
#17
JOURNAL ARTICLE
Anan S Jarab, Walid A AlQerem, Shrouq R Abu Heshmeh, Yazid N Al Hamarneh, Salah Aburuz, Judith Eberhardt
OBJECTIVES: This study investigated factors associated with anxiety and depression in COPD outpatients. METHODS: A cross-sectional study of 702 COPD outpatients from two major Jordanian hospitals using the Hospital Anxiety and Depression Scale (HADS) was conducted. RESULTS: Significant associations were found with gender (Anxiety OR: 5.29, 95%CI: 2.38-11.74; Depression OR: 0.20, 95%CI: 0.08-0.51), disease severity (Anxiety OR: 2.97, 95%CI: 1...
March 7, 2024: Expert Review of Respiratory Medicine
#18
JOURNAL ARTICLE
David A Palma, Houda Bahig, Andrew Hope, Stephen Harrow, Brock J Debenham, Alexander V Louie, Thi Trinh Thuc Toni Vu, Edith Filion, Andrea Bezjak, Marie-Pierre Campeau, Adele Duimering, Meredith E Giuliani, Joanna M Laba, Pencilla Lang, Benjamin H Lok, X Melody Qu, Srinivas Raman, George B Rodrigues, Christopher D Goodman, Stewart Gaede, Julie Morisset, Andrew Warner, Inderdeep Dhaliwal, Christopher J Ryerson
IMPORTANCE: Patients with interstitial lung disease (ILD) and early-stage non-small cell lung cancer (NSCLC) have been reported to be at high risk of toxic effects after stereotactic ablative radiotherapy (SABR), but for many patients, there are limited alternative treatment options. OBJECTIVE: To prospectively assess the benefits and toxic effects of SABR in this patient population. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study was conducted at 6 academic radiation oncology institutions, 5 in Canada and 1 in Scotland, with accrual between March 7, 2019, and January 12, 2022...
March 7, 2024: JAMA Oncology
#19
JOURNAL ARTICLE
María Cecilia Berón, Luciana Montalto, Diego Aquino, Rubén Quintana, Gisela Mayora, Marina Flores, Marisol Labas, Leticia Mesa
The Paraná River Delta in South America, a large wetlands macromosaic, faces threats from climate change, human activities like livestock intensification, and hydrological modifications driven by the construction of water management infrastructure to prevent flooding in productive lands. Macroinvertebrates, essential for wetland health, are affected by cattle-induced changes in water quality, nutrient enrichment, and trampling, posing challenges to the ecosystem's ecological balance and long-term survival of these organisms...
February 28, 2024: Environmental Research
#20
JOURNAL ARTICLE
Jennifer A Zader, Rudolf A Jörres, Imke Mayer, Peter Alter, Robert Bals, Henrik Watz, Pontus Mertsch, Klaus F Rabe, Felix Herth, Franziska C Trudzinski, Tobias Welte, Hans-Ulrich Kauczor, Jürgen Behr, Julia Walter, Claus F Vogelmeier, Kathrin Kahnert
BACKGROUND: Randomized controlled trials described beneficial effects of inhaled triple therapy (LABA/LAMA/ICS) in patients with chronic obstructive pulmonary disease (COPD) and high risk of exacerbations. We studied whether such effects were also detectable under continuous treatment in a retrospective observational setting. METHODS: Data from baseline and 18-month follow-up of the COPD cohort COSYCONET were used, including patients categorized as GOLD groups C/D at both visits (n = 258)...
March 1, 2024: BMC Pulmonary Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
